

Ji-Jin Yao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923870/publications.pdf>

Version: 2024-02-01

38
papers

569
citations

623734

14
h-index

677142

22
g-index

40
all docs

40
docs citations

40
times ranked

896
citing authors

#	ARTICLE	IF	CITATIONS
1	Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2569-2579.	2.5	2
2	Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 166, 118-125.	0.6	1
3	The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: A real-world study. <i>Head and Neck</i> , 2022, 44, 1404-1413.	2.0	3
4	The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study. <i>BMC Cancer</i> , 2022, 22, 505.	2.6	2
5	The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort. <i>Translational Oncology</i> , 2021, 14, 100990.	3.7	4
6	Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area. <i>Cancer Research and Treatment</i> , 2021, 53, 657-670.	3.0	12
7	Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study. <i>Radiotherapy and Oncology</i> , 2021, 161, 83-91.	0.6	7
8	The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4157-4166.	4.3	1
9	Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study. <i>Cancer Cell International</i> , 2021, 21, 604.	4.1	7
10	A deep-learning-based prognostic nomogram integrating microscopic digital pathology and macroscopic magnetic resonance images in nasopharyngeal carcinoma: a multi-cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097141.	3.2	22
11	Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). <i>BMC Medicine</i> , 2019, 17, 190.	5.5	64
12	Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. <i>Radiotherapy and Oncology</i> , 2019, 137, 137-144.	0.6	26
13	Treatment of Locally Advanced Nasopharyngeal Carcinoma by Helical Tomotherapy: An Observational, Prospective Analysis. <i>Translational Oncology</i> , 2019, 12, 757-763.	3.7	8
14	Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983386.	3.2	10
15	Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma. <i>EBioMedicine</i> , 2019, 42, 270-280.	6.1	49
16	Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. <i>Radiotherapy and Oncology</i> , 2019, 132, 178-187.	0.6	24
17	Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. <i>BMC Cancer</i> , 2019, 19, 37.	2.6	26
18	Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study. <i>Cancer Management and Research</i> , 2018, Volume 10, 6985-6996.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 82, 1-7.	1.5	31
20	Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial. <i>Translational Oncology</i> , 2018, 11, 1007-1011.	3.7	2
21	Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 285-292.	1.6	6
22	The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. <i>BMC Cancer</i> , 2018, 18, 740.	2.6	31
23	Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1102-1107.	3.4	18
24	Prognostic value of serum bilirubin in southern Chinese patients with advanced nasopharyngeal carcinoma. <i>Clinica Chimica Acta</i> , 2018, 484, 314-319.	1.1	8
25	Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. <i>Chinese Journal of Cancer</i> , 2017, 36, 26.	4.9	30
26	The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA. <i>Translational Oncology</i> , 2017, 10, 527-534.	3.7	6
27	Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 336-344.	4.9	15
28	Prognostic value of primary gross tumor volume and standardized uptake value of 18F-FDG in PET/CT for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831771784.	1.8	4
29	Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus <sc>DNA</sc>. <i>Cancer Science</i> , 2017, 108, 1640-1647.	3.9	23
30	Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?. <i>Journal of Cancer</i> , 2017, 8, 976-982.	2.5	29
31	Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2017, 36, 98.	4.9	29
32	Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis. <i>Journal of Cancer</i> , 2016, 7, 276-282.	2.5	4
33	A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. <i>Oncotarget</i> , 2016, 7, 21742-21752.	1.8	11
34	The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma: A Prospective Analysis. <i>Journal of Cancer</i> , 2016, 7, 2157-2164.	2.5	5
35	Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. <i>PLoS ONE</i> , 2016, 11, e0161878.	2.5	8
36	The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 20680-20690.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. Scientific Reports, 2015, 5, 13525.	3.3	14
38	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0131284.	2.5	4